Print Page   |   Contact Us   |   Sign In
Site Search

Annual Member Meeting Sponsors

Federal Issues

May 11th Update: PDUFA/MDUFA

Yesterday, May 10th, the House Energy and Commerce Committee approved H.R. 5651, the Food and Drug Administration Reform Act (including the reauthorization of PDUFA, and the other policy initiatives such as Accelerated Approval reform, conflicts of interest reform, etc.) by a vote of 46-0.  It is likely that this legislation will be considered by the House of Representatives in the next few weeks.

Here are a couple of high-level talking points talk to your congressional office prior to the legislation being considered on the House Floor:
  • This bill will enhance drug development by promoting greater FDA transparency and communication with industry.
  • The bill includes an enhanced accelerated approval pathway which will help expedite the development of new therapies for serious and life-threatening diseases, while maintaining the FDA’s high standard of safety effectiveness.
  • The bill also includes the permanent reauthorization of the Best Pharmaceuticals for Children Act (BPCA) and the Pediatric Equity Act (PREA) 


March 7th Update: BioForward on Capitol Hill for AdvaMed Fly-in

BioForward was in Washington D.C. on March 1, as a part of the AdvaMed fly-in.  Meetings took place with the offices of Wisconsin Senators Kohl and Johnson, as well as with the offices of Wisconsin Representatives Duffy, Ribble, Baldwin, Sensenbrenner, and Ryan and highlighted three important initiatives supporting medical device innovation:
Support was expressed for the reauthorization of the Medical Device User Fee Modernization Act (MDUFMA) and congressional representatives were urged to get the collaborative Industry-FDA agreement reauthorized before the previous agreement expired. 
Support was also expressed for the repeal of the Medical Device excise tax.  Currently there are five bills circulating that are looking to repeal said tax; one of which, Authored by Congressman Erik Paulsen, has 228 co-sponsors in the House. 
Finally, BioForward raised awareness about and recommended that legislators support the American Medical Isotopes Production Act, which would direct the secretary of DOE to implement a technology neutral program to evaluate the production of molybdenum-99 for medical uses.  Two Wisconsin companies, Shine Medical Technologies and Northstar Medical Radioistopes both just announced their production facilities for molybdenum-99 would be located in Southern Wisconsin and this legislation would impact them.

FDA speaks at 2011 BioForward Member Meeting

On December 14, 2011, BioForward hosted William H. Maisel, MD, MPH, Deputy Center Director for Science and Chief Scientist of the FDA's Center for Devices and Radiological Health as a speaker and to meet with area bioscience companies at a roundtable. You can view his presentation below on how the FDA is working to facilitate device innovation and bring important public health benefits to patients safely and quickly



BioForward Federal Advocacy Partners:

BioForward also partners with the following national organizations on federal issues:

AdvaMed advocates for a legal, regulatory and economic environment that advances global health care by assuring worldwide patient access to the benefits of medical technology. AdvaMed’s Federal Government Activities


BIO is the world's largest biotechnology organization, providing advocacy, business development and communications services for more than 1,100 members worldwide. BIO members are involved in the research and development of innovative healthcare, agricultural, industrial and environmental biotechnology products. BIO’s Federal Government Activities


MDMA (Medical Device Manufacturers Association)

MDMA, a national trade association that serves medical technology companies, plays a proactive role in helping to shape policy that impacts the medical device innovator. MDMA's Federal Government Activities


PhRMA's (Pharmaceutical Research and Manufacturer's Association) mission is to conduct effective advocacy for public policies that encourage discovery of important new medicines for patients by biopharmaceutical research companies. PhRMA’s Federal Government Activities